Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.
The proven beneficial effect of intravenous immunoglobulins (IVIg) in certain autoimmune disorders has led to the development of clinical trials in other autoimmune and systemic inflammatory diseases. In parallel, experimental studies are being carried out to better understand the mechanisms of action of IVIg. In this review, we discuss the clinical use of IVIg in autoimmune disorder and the possible mechanisms by which IVIg may be effective in the various diseases. A better understanding of the mechanisms of action of IVIg in autoimmune disease will allow optimization of their use as a therapeutic alternative to conventional immunosuppression.
Ronda
N
N
INSERM U28, Hôpital Broussais, Paris, France.
Hurez
V
V
Kazatchkine
M D
MD
D001327:Autoimmune Diseases / Q000628:therapy*; D002986:Clinical Trials as Topic; D005169:Factor VIII / Q000276:immunology; D006086:Graft vs Host Disease / Q000628:therapy; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007249:Inflammation / Q000628:therapy*; D008954:Models, Biological; D009080:Mucocutaneous Lymph Node Syndrome / Q000628:therapy; D011129:Polyradiculoneuropathy / Q000628:therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy; D014657:Vasculitis / Q000628:therapy
D007141:Immunoglobulin Fc Fragments; D007135:Immunoglobulin Variable Region; D016756:Immunoglobulins, Intravenous; D005169:Factor VIII